Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Hoffman

Showing results (71-80 of 83) with videos related to

Pageof 9
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 30, 2014
A phase II, open-label study of ramucirumab in combination with paclitaxel and carboplatin as first-line therapy in patients with stage IIIB/IV non-small-cell lung cancerD Ross Camidge, Eamon M Berge, Robert C Doebele, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|November 17, 2010
Safety and efficacy of thrombin-JMI: a multidisciplinary expert group consensusMohit Bhandari, Frederick A Ofosu, Nigel Mackman, et al.
The Laryngoscope|July 4, 2012
Association of candidate genes with nonsyndromic clefts in Honduran and Colombian populationsChristen J Lennon, Andrew C Birkeland, José Arturo Pacheco Nuñez, et al.
Clinical and Translational Science|December 19, 2020
Effects of Rovalpituzumab Tesirine on Ventricular Repolarization in Patients With Small-Cell Lung CancerJonathan W Goldman, Minal Barve, Jyoti D Patel, et al.
Blood|December 9, 2024
Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromesJacqueline S Garcia, Uwe Platzbecker, Olatoyosi Odenike, et al.
Ebiomedicine|January 13, 2019
A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancerRichard Tuli, Stephen L Shiao, Nicholas Nissen, et al.
Future Oncology (London, England)|March 30, 2018
Accelerating drug development in pediatric cancer: a novel Phase I study design of venetoclax in relapsed/refractory malignanciesAndrew E Place, Kelly Goldsmith, Jean-Pierre Bourquin, et al.
American Journal of Hematology|October 30, 2022
A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromesAmer M Zeidan, Uma Borate, Daniel A Pollyea, et al.
Vaccines|June 24, 2022
Serious Underlying Medical Conditions and COVID-19 Vaccine Hesitancy: A Large Cross-Sectional Analysis from AustraliaDaphne Day, Lisa Grech, Mike Nguyen, et al.
The AAPS Journal|June 26, 2014
Small molecule specific run acceptance, specific assay operation, and chromatographic run quality assessment: recommendation for best practices and harmonization from the global bioanalysis consortium harmonization teamsEric J Woolf, Stuart McDougall, Douglas M Fast, et al.
Pageof 9

Showing results (71-80 of 83) with videos related to

Sort By:
Pageof 9
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 30, 2014
A phase II, open-label study of ramucirumab in combination with paclitaxel and carboplatin as first-line therapy in patients with stage IIIB/IV non-small-cell lung cancerD Ross Camidge, Eamon M Berge, Robert C Doebele, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|November 17, 2010
Safety and efficacy of thrombin-JMI: a multidisciplinary expert group consensusMohit Bhandari, Frederick A Ofosu, Nigel Mackman, et al.
The Laryngoscope|July 4, 2012
Association of candidate genes with nonsyndromic clefts in Honduran and Colombian populationsChristen J Lennon, Andrew C Birkeland, José Arturo Pacheco Nuñez, et al.
Clinical and Translational Science|December 19, 2020
Effects of Rovalpituzumab Tesirine on Ventricular Repolarization in Patients With Small-Cell Lung CancerJonathan W Goldman, Minal Barve, Jyoti D Patel, et al.
Blood|December 9, 2024
Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromesJacqueline S Garcia, Uwe Platzbecker, Olatoyosi Odenike, et al.
Ebiomedicine|January 13, 2019
A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancerRichard Tuli, Stephen L Shiao, Nicholas Nissen, et al.
Future Oncology (London, England)|March 30, 2018
Accelerating drug development in pediatric cancer: a novel Phase I study design of venetoclax in relapsed/refractory malignanciesAndrew E Place, Kelly Goldsmith, Jean-Pierre Bourquin, et al.
American Journal of Hematology|October 30, 2022
A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromesAmer M Zeidan, Uma Borate, Daniel A Pollyea, et al.
Vaccines|June 24, 2022
Serious Underlying Medical Conditions and COVID-19 Vaccine Hesitancy: A Large Cross-Sectional Analysis from AustraliaDaphne Day, Lisa Grech, Mike Nguyen, et al.
The AAPS Journal|June 26, 2014
Small molecule specific run acceptance, specific assay operation, and chromatographic run quality assessment: recommendation for best practices and harmonization from the global bioanalysis consortium harmonization teamsEric J Woolf, Stuart McDougall, Douglas M Fast, et al.
Pageof 9